Dr. Moreau on Tourmaline-MM1 Study for Multiple Myeloma

January 7, 2016
Philippe Moreau, MD

Philippe Moreau, MD, head of Department of Hematology, Centre Hospitalier et Universitaire, Nantes, France, discusses the phase III Tourmaline-MM1 study for patients with relapsed/refractory multiple myeloma.

Philippe Moreau, MD, head of Department of Hematology, Centre Hospitalier et Universitaire, Nantes, France, discusses the phase III Tourmaline-MM1 study for patients with relapsed/refractory multiple myeloma.

The prospective, randomized, double-blind, placebo-controlled study compared lenalidomide and dexamethasone plus ixazomib versus lenalidomide and dexamethasone plus placebo. The trial’s primary endpoint was progression-free survival (PFS). There were 722 patients enrolled in the study who had relapsed/refractory disease and who received one to three prior lines of therapy.

Results showed that the duration of response and PFS were both improved in patients in the ixazomib arm. Median PFS increased to 20.6 months from 14.7 months without a substantial increase in overall toxicity, Moreau says. All subgroups of patients benefitted from the addition of ixazomib, including those with high-risk cytogenetics and 17p deletion, he adds.


x